Stock Analysis
- United Kingdom
- /
- Biotech
- /
- AIM:ETX
e-therapeutics Full Year 2023 Earnings: UK£0.015 loss per share (vs UK£0.017 loss in FY 2022)
e-therapeutics (LON:ETX) Full Year 2023 Results
Key Financial Results
- Net loss: UK£8.27m (loss widened by 2.5% from FY 2022).
- UK£0.015 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
e-therapeutics shares are up 8.0% from a week ago.
Risk Analysis
You should learn about the 5 warning signs we've spotted with e-therapeutics (including 2 which can't be ignored).
Valuation is complex, but we're helping make it simple.
Find out whether e-therapeutics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:ETX
e-therapeutics
e-therapeutics plc engages in drug discovery research activities in the United Kingdom.
Flawless balance sheet and slightly overvalued.